News
-
2025-10 23MORE
3D Medicines Completed Follow-Up for the First Patient in Global Exclusive Low-Dose RDC Candidate 3D1015 Human Data Trial
Shanghai, China – On October 23, 2025, 3D Medicines (1244.HK) announced the successful completion of follow-up for the first patient enrolled in the investigator-initiated trial (IIT) of 3D1015, its core radioligand drug conjugate (RDC) candidate.
-
2025-10 22MORE
2025 ESMO | 恩维达®’s Multiple Research Achievements Presented and Shined in Berlin, Germany
As one of the world's most influential oncology conferences, the European Society for Medical Oncology (ESMO) has long been dedicated to advancing global efforts in cancer research and treatment. The ESMO Congress 2025 was successfully held in Berlin, Germany, from October 17 to 21, 2025 (local time), in a hybrid format combining in-person and virtual participation. The congress showcased a wealth of cutting-edge clinical research findings and brought together leading international experts to discuss emerging trends in oncology therapeutics and patient management. Notably, multiple studies on Envafolimab® (Envafolimab Injection) were selected for presentation, highlighting its growing scientific and clinical impact.
-
2025-02 08MORE
3D Medicines Appoints Mr. Gan Ding as Chief Commercial Officer
February 8th, 2025, Shanghai, China—3D Medicines Inc. (1244.HK) today announced the appointment of Mr. Gan Ding as Chief Commercial Officer (CCO). With three decades of experience in the biopharmaceutical industry across China, the United States, and internationally, Mr. Ding brings a wealth of expertise that will drive the future commercial development of 3D Medicines.
-
2024-05 13MORE
The latest academic progress – 恩维达® has entered the consensus of gastric cancer surgery for the first time, and the data of advanced biliary tract cancer will be presented in the APASL oral report
With the widespread clinical application of the subcutaneous injection of PD-L1 antibody drug 恩维达® (Envafolimab)in tumor treatment, good news of i...
-
2023-10 30MORE
VOLUNTARY ANNOUNCEMENT APPROVAL FROM FDA TO PROCEED WITH A GLOBAL PHASE III TRIAL FOR TREATMENT OF THE FIRST LINE MISMATCH REPAIR PROFICIENT (pMMR) ADVANCED OR RECURRENT ENDOMETRIAL CANCER
VOLUNTARY ANNOUNCEMENT APPROVAL FROM FDA TO PROCEED WITH A GLOBAL PHASE III TRIAL FOR TREATMENT OF THE FIRST LINE MISMATCH REPAIR PROFICIENT (pMMR) ADVANCED OR RECURRENT ENDOMETRIAL CANCER
-
2022-12 15MORE
3D Medicines Inc. Successfully Listed on the Main Board of HKEX，Stock code：1244.HK
(Hong Kong, December 15 , 2022) A biopharmaceutical company in China for the development and commercialization of next-generation tumor immunotherapy drugs - 3D Medicines Inc. (“ 3D Medicines” or the “Company”, Stock Code: 1244.HK), has successfully listed and commenced dealings on the Main Board of the Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange”) today.
